EW · Edwards Lifesciences Corporation
$90.782026-07-21Sector: Healthcare; Industry: Medical - Devices; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$69
-23.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($58 · $72) Analysts Range ($85 · $110) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $5.0B | — | 33.0% | 11.0% | $1.5B | −$1.2B | $305MM | 7.8% | — | 16.6% | $8.8B | $2.42 | — |
| 2024.Q4 | $5.0B | 0.0% | 33.0% | 9.8% | $1.5B | $2.3B | $3.8B | 8.6% | — | 16.3% | $9.4B | $2.42 | — |
| 2025.Q1 | $5.4B | 8.6% | 29.3% | 10.9% | $1.4B | $2.6B | $4.0B | 8.3% | — | 14.7% | $9.9B | $7.19 | — |
| 2025.Q4 | $5.4B | 0.0% | 29.3% | 17.0% | $1.3B | −$327MM | $996MM | 8.5% | — | 13.4% | $9.8B | $7.19 | — |
| 2026.Q1 | $6.3B | 15.9% | 31.9% | 17.3% | $1.7B | −$724MM | $941MM | 8.1% | — | 16.5% | $10.4B | $1.88 | 26.2 |
| italics below = DCF projection · 10yr Rev CAGR: 7.9% |
| 2027.Q1 | $6.9B | +10.1% | 31.3% | 17.6% | $1.8B | −$147MM | $1.6B | 8.0% | $1.5B | 17.1% | $10.6B | $2.67 | 34.0 |
| 2028.Q1 | $7.6B | +9.9% | 32.1% | 17.9% | $2.0B | −$175MM | $1.8B | 8.1% | $1.6B | 18.9% | $10.7B | $3.00 | 30.3 |
| 2029.Q1 | $8.4B | +10.0% | 32.6% | 18.1% | $2.2B | −$213MM | $2.0B | 8.2% | $1.6B | 20.7% | $10.9B | $3.34 | 27.2 |
| 2030.Q1 | $9.2B | +9.6% | 32.9% | 18.4% | $2.5B | −$254MM | $2.2B | 8.2% | $1.6B | 22.3% | $11.2B | $3.68 | 24.7 |
| 2031.Q1 | $10.0B | +9.1% | 32.9% | 18.7% | $2.7B | −$299MM | $2.4B | 8.3% | $1.6B | 23.7% | $11.5B | $4.00 | 22.7 |
|
| Term. Yr+ | $14.0B | 4.1% | 22.6% | 20.0% | $2.5B | −$535MM | $2.0B | 8.6% | $20.1B | 19.4% | — | — | — |
Active scenario IV: $69 (-23.7% vs market)